Publicacións en colaboración con investigadores/as de Hospital Clinico Universitario de Valencia (17)

2023

  1. Cardiorenal benefits of finerenone: protecting kidney and heart

    Annals of Medicine, Vol. 55, Núm. 1, pp. 502-513

  2. Clinical Benefit of Bempedoic Acid in Randomized Clinical Trials

    The American journal of cardiology, Vol. 205, pp. 321-324

  3. Finerenone: towards a holistic therapeutic approach to patients with diabetic kidney disease

    Nefrologia, Vol. 43, Núm. 4, pp. 386-398

  4. Impact of dapagliflozin on cardiac remodelling in patients with chronic heart failure: The DAPA-MODA study

    European Journal of Heart Failure, Vol. 25, Núm. 8, pp. 1352-1360

  5. The efficacy of intensive lipid-lowering therapies on the reduction of LDLc and of major cardiovascular events

    Journal of Clinical Lipidology, Vol. 17, Núm. 5, pp. 602-611

2022

  1. Mortality and Heart Failure Risk Reductions in Patients Treated With Sacubitril-Valsartan in Clinical Trials

    American journal of therapeutics, Vol. 29, Núm. 5, pp. e572-e575

2021

  1. Lipid lowering treatment in patients with very high risk cardiovascular disease. Spanish Society of Cardiology Consensus Document for the use of PCSK9 inhibitors in clinical practice

    REC: CardioClinics, Vol. 56, Núm. 1, pp. 39-48

  2. Long-term prognosis of women with Brugada syndrome and electrophysiological study

    Heart Rhythm, Vol. 18, Núm. 5, pp. 664-671

2018

  1. Long-term prognosis of patients with life-threatening ventricular arrhythmias induced by coronary artery spasm

    Europace, Vol. 20, Núm. 5, pp. 851-858

2015

  1. Las guías de práctica clínica de manejo de la dislipemia. Una visión transatlántica

    Revista Espanola de Cardiologia Suplementos

2014

  1. Validación de EuroSCORE II en España

    Cirugia Cardiovascular, Vol. 21, Núm. 4, pp. 246-251

2011

  1. Anticoagulation prescription in atrial fibrillation

    Expert Opinion on Pharmacotherapy, Vol. 12, Núm. 10, pp. 1473-1479

  2. Clustering of target organ damage increases mortality after acute coronary syndromes in patients with arterial hypertension

    Journal of Human Hypertension, Vol. 25, Núm. 10, pp. 600-607

2010

  1. Usefulness of an abnormal ankle-brachial index for detecting multivessel coronary disease in patients with acute coronary syndrome

    Revista Espanola de Cardiologia, Vol. 63, Núm. 1, pp. 54-59

2009

  1. Erectile dysfunction as a marker of silent cardiovascular disease in type-2 diabetic patients in Spain. The DIVA (DIabetes and VAscular disease) study

    Medicina Clinica, Vol. 132, Núm. 8, pp. 291-297

2008

  1. Prevalence and Prognostic Influence of Peripheral Arterial Disease in Patients ≥40 Years Old Admitted into Hospital Following an Acute Coronary Event

    European Journal of Vascular and Endovascular Surgery, Vol. 36, Núm. 2, pp. 189-196

2007

  1. Prevalencia del síndrome metabôlico en pacientes con enfermedad cardiovascular en España: Estudio CLYDIA

    Medicina Clinica, Vol. 128, Núm. 11, pp. 407-413